阿替普酶与尿激酶治疗急性肺栓塞溶栓的有效性及安全性分析

Efficacy and Safety of Urokinase for Acute Pulmonary Embolism in Patients With Acute Pulmonary Embolism

目的研究阿替普酶与尿激酶治疗急性肺栓塞溶栓的临床效果及安全性。方法选取我院收治的76例急性肺栓塞患者（2015年1月-2016年4月）,随机化分为对照组（采用尿激酶治疗）和观察组（采用阿替普酶治疗）,各38例。对比两组间疗效。结果观察组的总有效率为97.37%,优于对照组（P〈0.05）,而不良反应发生率及死亡率方面两组差异无统计学意义。结论急性肺栓塞溶栓治疗中使用阿替普酶,疗效更好,安全性更高。

Objective To study the clinical efficacy and safety of urokinase for acute pulmonary embolism. Methods 76 cases of acute pulmonary embolism（from January 2015 to April 2016） were chosen, and randomized into the control group（using urokinase treatment） and the observation group（using the treatment of the treatment of the treatment of the enzyme）, each of 38 cases. Compare the efficacy between the two groups. Results The total effective rate of the observation group was 97.37%, better than that of the control group（P〈0.05）, and the incidence of adverse reactions and the low mortality rate. Conclusion The use of the enzyme in the treatment of acute pulmonary embolism thrombolysis is better, and the safety is higher.